DKK1

Leap Therapeutics to Present Updated Data from Part A of the DisTinGuish Study of DKN-01 Plus Tislelizumab and Chemotherapy in Gastric Cancer Patients at the 2023 ASCO Annual Meeting

Retrieved on: 
Thursday, May 25, 2023
GEA, Mitt, Therapy, Progression-free survival, DKK1, BeiGene, Distinguishing, Survival, OS, Quality of life, Toxicity, Associate, Harvard Medical School, ASCO, ORR, American Society of Clinical Oncology, MD, LEAP, Patient, Annual general meeting, PD-1, Medicare Part D coverage gap, Society, PD-L1, SD, PR, Tislelizumab, Health insurance, Pharmaceutical industry, Palladium

"Median overall survival and progression-free survival for patients treated with DKN-01 plus tislelizumab and chemotherapy exceeded current PD-1 combination benchmarks, especially for those patients with low expression of PD-L1.

Key Points: 
  • "Median overall survival and progression-free survival for patients treated with DKN-01 plus tislelizumab and chemotherapy exceeded current PD-1 combination benchmarks, especially for those patients with low expression of PD-L1.
  • Together with the previously reported data on the encouraging outcomes with DKN-01 for patients with high DKK1 expression, these results provide strong support for the ongoing randomized controlled clinical trial in first-line GEA patients."
  • "We are excited about the latest data from Part A of the DisTinGuish study which continues to show DKN-01 plus tislelizumab and chemotherapy as a safe and active treatment where tumor reductions can continue to deepen over time.
  • We look forward to completing enrollment in the randomized controlled clinical trial late this year and seeing data from our ongoing colorectal cancer trial in the coming months."

Leap Therapeutics Acquires Flame Biosciences

Retrieved on: 
Tuesday, January 17, 2023
Janus, DKK1, Cancer, Merck, Therapy, Series, Stomach, Colorectal cancer, Biomarker, Randomized controlled trial, Securities and Exchange Commission (Nigeria), Endometrial cancer, Patient, Public research and development, BeiGene, PD-L1, Antibody, Exercise, Pharmaceutical industry, Management, Security (finance), LEAP, Flame, Citadel

CAMBRIDGE, Mass., Jan. 17, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, and Flame Biosciences, Inc., a privately-held biotechnology company, today announced that the companies have entered into a definitive merger agreement pursuant to which Leap has acquired Flame and its assets, including FL-301, its clinical stage anti-Claudin18.2 monoclonal antibody, FL-302, its preclinical anti-Claudin18.2/CD137 bispecific monoclonal antibody, FL-501, its preclinical anti-GDF15 monoclonal antibody, and net cash of approximately $50 million as of December 31, 2022.

Key Points: 
  • ET today
    CAMBRIDGE, Mass., Jan. 17, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, and Flame Biosciences, Inc., a privately-held biotechnology company, today announced that the companies have entered into a definitive merger agreement pursuant to which Leap has acquired Flame and its assets, including FL-301, its clinical stage anti-Claudin18.2 monoclonal antibody, FL-302, its preclinical anti-Claudin18.2/CD137 bispecific monoclonal antibody, FL-501, its preclinical anti-GDF15 monoclonal antibody, and net cash of approximately $50 million as of December 31, 2022.
  • It was clear that the Leap development team, with its expertise in developing DKN-01, was the ideal partner for FL-301, our preclinical assets, and the Flame shareholders," said Patricia Martin, the Co-Chief Executive Officer of Flame.
  • Leap has agreed to file a registration statement with the U.S. Securities and Exchange Commission (the "SEC") to register the resale by the Flame stockholders of the shares of Leap common stock to be issued in connection with the merger.
  • Leap has added two members nominated by Flame to its existing eight person Board of Directors: Patricia Martin and Christian Richard.

Leap Therapeutics to Participate at the Piper Sandler 34th Annual Healthcare Conference

Retrieved on: 
Monday, November 21, 2022
Oncology nursing, Growth, Conference, Therapy, Piper Sandler Companies, Annual report, Patient, COVID-19, Risk, DKK1, EDGAR, Pharmaceutical industry, LEAP, BeiGene

CAMBRIDGE, Mass., Nov. 21, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi, President and Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference, being held in New York on November 29-December 1, 2022.

Key Points: 
  • CAMBRIDGE, Mass., Nov. 21, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi, President and Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference, being held in New York on November 29-December 1, 2022.
  • Leap Therapeutics (Nasdaq: LPTX) is focused on developing targeted and immuno-oncology therapeutics.
  • Leap has entered into a strategic collaboration with BeiGene, Ltd. for the rights to develop DKN-01 in Asia (excluding Japan), Australia, and New Zealand.
  • For more information about Leap Therapeutics, visit http://www.leaptx.com or view our public filings with the SEC that are available via EDGAR at http://www.sec.gov or via https://investors.leaptx.com/ .

Leap Therapeutics to Present Updated Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab and Preclinical Data in Colorectal Cancer Models at the SITC Annual Meeting

Retrieved on: 
Monday, November 7, 2022
Associate, ORR, DKK1, Company, Randomized controlled trial, Private Securities Litigation Reform Act, Progression-free survival, Therapy, Tislelizumab, Growth, GEA, Bevacizumab, Society for Immunotherapy of Cancer, Part, Colorectal cancer, Trial of the century, Population, Death, CRC, Journal of Environmental Science and Health, Part C, Neoplasm, Securities Exchange Act of 1934, Large intestine, COVID-19, Nasdaq, Distinguishing, Harvard Medical School, Securities Act of 1933, Defiance, Annual general meeting, PD-L1, Annual report, Korea, Drug Quality and Security Act, Risk, CPS, PD, South Korea, SD, SEC, Society, SITC, Patient, MD, EDGAR, Pharmaceutical industry, Palladium, Cancer, BeiGene, Immunotherapy, LEAP

CAMBRIDGE, Mass., Nov. 7, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused  on developing targeted and immuno-oncology therapeutics, today announced the Company will be presenting updated data from Part B of the DisTinGuish study evaluating DKN-01 in combination with tislelizumab, BeiGene's anti-PD-1 antibody, in second-line gastroesophageal adenocarcinoma (GEA) cancer patients whose tumors express high levels of DKK1 (DKK1-high) at the Society of Immunotherapy for Cancer (SITC) 37th Annual Meeting being held in Boston, MA on November 8-12, 2022.

Key Points: 
  • As DKK1-high patients appear to have more aggressive disease, the updated second-line DKN-01 plus tislelizumab Part B data provides further evidence of activity in this difficult-to-treat patient population, particularly among the DKK1-high/PD-L1-high patients.
  • These results continue to support the decision to start Part C, the randomized controlled clinical trial in first-line patients."
  • "Colorectal cancer is the third most frequent cancer globally and the second leading cause of death.
  • Leap is conducting this combination study as part of an exclusive option and license agreement with BeiGene.

Leap Therapeutics to Participate at the Baird 2022 Global Healthcare Conference

Retrieved on: 
Wednesday, September 7, 2022
COVID-19, Securities Exchange Act of 1934, Securities Act of 1933, Therapy, DKK1, SEC, Conference, Nasdaq, EDGAR, Investor, Risk, Annual report, Oncology nursing, Private Securities Litigation Reform Act, Growth, Patient, Pharmaceutical industry, LEAP, BeiGene

CAMBRIDGE, Mass., Sept. 7, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi, President and Chief Executive Officer, will participate in a fireside chat at the Baird 2022 Global Healthcare Conference, being held in New York on September 13-14, 2022.

Key Points: 
  • CAMBRIDGE, Mass., Sept. 7, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi, President and Chief Executive Officer, will participate in a fireside chat at the Baird 2022 Global Healthcare Conference, being held in New York on September 13-14, 2022.
  • Leap Therapeutics (Nasdaq: LPTX) is focused on developing targeted and immuno-oncology therapeutics.
  • Leap has entered into a strategic collaboration with BeiGene, Ltd. for the rights to develop DKN-01 in Asia (excluding Japan), Australia, and New Zealand.
  • For more information about Leap Therapeutics, visit http://www.leaptx.com or view our public filings with the SEC that are available via EDGAR at http://www.sec.gov or via https://investors.leaptx.com/ .

Leap Therapeutics' Board of Directors Member Dr. Monica Bertagnolli Appointed as the Director of the National Cancer Institute

Retrieved on: 
Friday, August 12, 2022
Hospital, ASCO, BeiGene, CEO, NewYork-Presbyterian Hospital, American Society of Clinical Oncology, Division, Dana–Farber Cancer Institute, SEC, Leadership, Cancer, National academy, Board, Director, LLC, Colorectal Cancer Alliance, Cancer Breakthroughs 2020, Clinical trial, Brigham and Women's Hospital, EDGAR, Patient, Therapy, NCI, Harvard Medical School, Surgical oncology, DKK1, Weill Cornell Medicine, National Academy of Medicine, National Cancer Institute, Alliance for Clinical Trials in Oncology, Nasdaq, MD, National, Dana, Pharmaceutical industry, LEAP

CAMBRIDGE, Mass., Aug. 12, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics today announced that its Board member, Monica Bertagnolli, MD, has been appointed as the 16th Director of the National Cancer Institute (NCI) by the Biden administration. Dr. Bertagnolli becomes the first woman director of the institute since its inception in 1937. Effective with her appointment, Dr. Bertagnolli will transition off Leap's Board of Directors.

Key Points: 
  • Dr. Bertagnolli becomes the first woman director of the institute since its inception in 1937.
  • Effective with her appointment, Dr. Bertagnolli will transition off Leap's Board of Directors.
  • Dr. Bertagnolli is currently a professor of surgery at Harvard Medical School, and an associate surgeon at Brigham and Women's Hospital and Dana-Farber Cancer Institute.
  • Dr. Bertagnolli has served on numerous committees and boards including the Board of Directors for ASCO and the National Academy of Medicine's National Cancer Policy Forum.

Leap Therapeutics to Present Initial Data from the Investigator-Sponsored Study of DKN-01 Plus Docetaxel in Patients with Prostate Cancer at the 2022 ASCO Annual Meeting

Retrieved on: 
Thursday, May 26, 2022
Risk, NYU Langone Health, Neoplasm, Annual general meeting, Private Securities Litigation Reform Act, EDGAR, Nasdaq, Doctor of Philosophy, BeiGene, Patient, RECIST, Therapy, MCRPC, Docetaxel, Society, COVID-19, American Society of Clinical Oncology, Management of prostate cancer, Securities Act of 1933, DLT, Securities Exchange Act of 1934, Histology, Time, DKK1, Prostate cancer, Safety, ASCO, Drug Quality and Security Act, Infrared spectroscopy correlation table, Acquisition, SEC, MD, Annual report, Pharmaceutical industry, Medical imaging, LEAP

"As the initial data show, DKN-01 in combination with docetaxel is a promising therapy option for prostate cancer patients, particularly for those with aggressive variant prostate cancer," said David Wise, MD, PhD, Medical Oncologist at Perlmutter Cancer Center, NYU Langone Health and principal investigator on the study.

Key Points: 
  • "As the initial data show, DKN-01 in combination with docetaxel is a promising therapy option for prostate cancer patients, particularly for those with aggressive variant prostate cancer," said David Wise, MD, PhD, Medical Oncologist at Perlmutter Cancer Center, NYU Langone Health and principal investigator on the study.
  • Key Initial Findings from the Investigator-Sponsored Phase 1b/2a Clinical Trial:
    Data that will be presented at ASCO is from the completed Phase 1 portion of the study.
  • Thirteen patients were enrolled, with 7 patients in the DKN-01 monotherapy cohort and 6 patients in the DKN-01 plus docetaxel combination cohort.
  • The study also aims to study correlations between DKK1 expression and tumor genetics, histology and anti-tumor activity.

Leap Therapeutics Reports First Quarter 2022 Financial Results

Retrieved on: 
Friday, May 13, 2022
Company, Risk, Private Securities Litigation Reform Act, Research, Docetaxel, Survival, EDGAR, Nasdaq, Medicare Part D, Progression-free survival, Patient, Tislelizumab, Therapy, ORR, Clinical trial, Stomach, COVID-19, Myeloid-derived suppressor cell, Great Leap Forward, Cancer, Prostate cancer, Companion diagnostic, PFS, Securities Exchange Act of 1934, Securities Act of 1933, DKK1, NK, NYU Langone Health, ASCO, Drug Quality and Security Act, Leica Biosystems, Leica, Distinguishing, Growth, Outline, Annual report, Pharmaceutical industry, Medical imaging, Cryptocurrency, Part, LEAP, BeiGene, New York University

CAMBRIDGE, Mass., May 13, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the first quarter endedMarch 31, 2022.

Key Points: 
  • CAMBRIDGE, Mass., May 13, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the first quarter endedMarch 31, 2022.
  • Net Loss was$10.4 millionfor the first quarter 2022, compared to$9.1 millionfor the same period in 2021.
  • Research and development expenses were $7.8 millionfor the first quarter 2022, compared to$6.8 millionfor the same period in 2021.
  • General and administrative expenses were$2.8 millionfor the first quarter 2022, compared to$2.7 millionfor the same period in 2021.

Leap Therapeutics to Present at Raymond James 43rd Annual Institutional Investors Conference

Retrieved on: 
Wednesday, March 2, 2022
Risk, Prostate Cancer Foundation, Private Securities Litigation Reform Act, DKK1, Great Leap Forward, Patient, Investor, Securities Exchange Act of 1934, Annual report, Growth, Therapy, COVID-19, Conference, Securities Act of 1933, EDGAR, LEAP, Partnership, Nasdaq, Pharmaceutical industry, BeiGene

CAMBRIDGE, Mass., March 2, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi, President and Chief Executive Officer will present a corporate overview at Raymond James Institutional Investors Conference, being held in Orlando on March 6-9, 2022.

Key Points: 
  • CAMBRIDGE, Mass., March 2, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi, President and Chief Executive Officer will present a corporate overview at Raymond James Institutional Investors Conference, being held in Orlando on March 6-9, 2022.
  • Leap Therapeutics(Nasdaq: LPTX) is focused on developing targeted and immuno-oncology therapeutics.
  • Leap has entered into a strategic partnership with BeiGene, Ltd. for the rights to develop DKN-01 inAsia(excludingJapan),Australia, and New Zealand.
  • For more information aboutLeap Therapeutics, visit http://www.leaptx.com or view our public filings with theSECthat are available via EDGAR at http://www.sec.gov or via https://investors.leaptx.com/ .

Leica Biosystems and Leap Therapeutics Partner on Companion Diagnostic to Advance Care for Cancer Patients

Retrieved on: 
Monday, January 31, 2022
Diagnosis, Leica Biosystems, EDGAR, Patient, Leica, Therapy, Pathology, Immune system, Workflow, NASDAQ, BeiGene, LEAP, Neoplasm, Radiology, SEC, Nature, Research, Cancer, Partnership, Disease, Drug discovery, Prostate cancer screening, Biopsy, SRL Diagnostics, Heart, Translational medicine, Bio-Techne, DKK1, Pharmaceutical industry, Medical imaging

The assay will be used to support clinical development of Leap Therapeutics' anti-DKK1 cancer therapy, DKN-01, currently being studied in clinical trials.

Key Points: 
  • The assay will be used to support clinical development of Leap Therapeutics' anti-DKK1 cancer therapy, DKN-01, currently being studied in clinical trials.
  • Leap Therapeutics is currently advancing the development of DKN-01, a humanized monoclonal antibody that targets DKK1, to treat cancer.
  • "Companion Diagnostics are a step toward treating cancer patients based on the biomarker makeup of their disease," said Rachel Skelton, Senior Director of Pharma Partnerships at Leica Biosystems.
  • "We are excited to partner with Leap to advance cancer care."